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ABSTRACT
Triplex-forming oligonucleotides (TFOs) bind DNA
in a sequence-specific manner at polypurine/poly-
pyrimidine sites and mediate targeted genome modi-
fication. Triplexes are formed by either pyrimidine
TFOs, which bind parallel to the purine strand of the
duplex (pyrimidine, parallel motif), or purine TFOs,
which bind in an anti-parallel orientation (purine,
anti-parallel motif). Both purine and pyrimidine
TFOs, when linked to psoralen, have been shown to
direct psoralen adduct formation in cells, leading to
mutagenesis or recombination. However, only purine
TFOs have been shown to mediate genome modifica-
tion without the need for a targeted DNA-adduct. In
thiswork,wereporttheabilityofaseriesofpyrimidine
TFOs, with selected chemical modifications, to
induce repair and recombination in two distinct epi-
somal targets in mammalian cells in the absence
of any DNA-reactive conjugate. We find that TFOs
containing N30P50 phosphoramidate (amidate),
5-(1-propynyl)-20-deoxyuridine (pdU), 20-O-methyl-
ribose (20-O-Me), 20-O-(2-aminoethyl)-ribose, or 20-O,
40-C-methylene bridged or locked nucleic acid (LNA)-
modified nucleotides show substantially increased
formation of non-covalent triplexes under physiolo-
gical conditions compared with unmodified DNA
TFOs. However, of these modified TFOs, only the
amidate and pdU-modified TFOs mediate induced
recombination in cells and stimulate repair in cell
extracts, at levels comparable to those seen with
purine TFOs in similar assays. These results show
that amidate and pdU-modified TFOs can be used
as reagents to stimulate site-specific gene targeting
without the need for conjugation to DNA-reactive
molecules. By demonstrating the potential for
induced repair and recombination with appropriately
modified pyrimidine TFOs, this work expands the
options available for triplex-mediated gene targeting.
INTRODUCTION
Triplex-forming oligonucleotides (TFOs) provide potential
tools for altering gene function by either repressing transcrip-
tion, inhibiting DNA replication or inducing site-speciﬁc
mutagenesis and recombination (1–6). TFOs bind in the
major groove of DNA in a sequence-speciﬁc manner to poly-
purine/polypyrimidine sequences, in two distinct motifs
(7–10). TFOs in the purine motif bind anti-parallel to the
purine strand of the duplex via reverse-Hoogsteen hydrogen
bonds and TFOs in the pyrimidine motif bind in a parallel
orientation viaHoogsteen bonds(7–10).Thethird-strandbind-
ing code speciﬁes that in the purine motif G and A in the third
strand bind to the duplex G and A, respectively; while in
the pyrimidine motif C and T bind to the duplex G and A,
respectively (11).
Binding afﬁnity in the two motifs is differentially affected
by pH and ion concentrations. In the pyrimidine motif, the
need for protonation of cytosines at the N3 position (favored
at low pH) limits the binding afﬁnity of TFOs composed of
unmodiﬁed DNA under physiological conditions (12). In order
to make TFOs more effective tools, chemical modiﬁcations
have been developed to enhance third-strand binding under
in vivo conditions. Base modiﬁcations such as 5-methyl-20-
deoxycytidine (5meC) and 5-methyl-20-deoxyuridine (pdU)
and sugar modiﬁcations such as 20-O-(2-aminoethyl)-ribose
(20-AE) substitution improve binding afﬁnity and psoralen
delivery in the pyrimidine motif (13,14). Pyrimidine TFOs
with an amidate backbone (in which nitrogen replaces the
bridging 30 oxygen of the diester) have also been shown to
form stable triplexes at neutral pH (15).
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acridine to TFOs has been shown to further increase their
biological activity (16). Although purine TFOs consisting
of standard DNA [except for 30 end-capping (4,17)] have
been shown to be active in cells and animals (16–18), fewer
strategies have been established for effective modiﬁcation of
purine TFOs. The most effective option that has been demon-
strated is backbone substitution with N,N-diethylethylene-
diamine (DEED) internucleoside linkages which reduce
the Mg
2+-dependence and enhance intracellular activity of
polypurine TFOs (18).
Both purine and appropriately modiﬁed pyrimidine TFOs
have been used to direct psoralen intercalation and photoad-
duct formation to speciﬁc sites in mammalian cells and yeast
(16,17,19). In the absence of psoralen, however, only purine
TFOs have been shown to induce genomic changes (either
mutagenesis or recombination) via the effects of third-
strand binding alone (4). Previous work has demonstrated
that non-covalent triplexes formed by purine TFOs are active
in stimulating repair and recombination in cell extracts, in cell
culture and even in mice (3,5,20,21). Studies in human cell
extracts and in DNA repair-deﬁcient human cell lines have
revealed the ability of non-covalent purine motif triplexes to
provoke recombination in a manner dependent on the nucle-
otide excision repair (NER) pathway (4). However, the ability
of non-covalent triplexes formed by pyrimidine TFOs to
induce recombination has not been established.
In the work reported here, we sought to determine the extent
to which triplexes formed by pyrimidine TFOs can stimulate
recombination and repair. Because standard DNA TFOs bind
poorly in the pyrimidine motif, we evaluated TFOs containing
a series of modiﬁcations to determine which, if any, are effect-
ive in provoking DNA metabolism via third-strand binding
alone, in the absence of a DNA-reactive conjugate. Interest-
ingly, although several modiﬁcations did support high-afﬁnity
binding under physiological conditions in vitro, only amidate
and pdU-modiﬁed TFOs induced recombination in episomal
targets in cells and repair in cell extracts. These results dem-
onstrate that certain pyrimidine TFOs can provoke recomb-
ination without the need for covalent damage to the DNA.
Because pyrimidine triplexes are favored at A:T bp-rich sites
(in contrast to purine triplexes, which are favored at G:C-rich
sites), these ﬁndings increase the number of potential genomic
target sites suitable for modiﬁcation by non-covalent triplexes.
In addition, we propose a model in which TFO sugar substi-
tution at the 20 position may inﬂuence the extent to which the
resulting triplex can provoke DNA metabolism, with reference
to NMR studies showing that 20 substitution of the TFO inﬂu-
ences the degree of structural distortion of the duplex to which
the TFO is bound (22).
MATERIALS AND METHODS
Oligonucleotides and vectors
Oligonucleotides were obtained from Transgenomic (amid-
ate18), Gilead Sciences and Eurogentec (G3pUmC18), Oligos
Etc. (G3TmC18, 20-O-Me18), Proligo (LNA18, LNAcontrol)
and Eurogentec (LNA18, UmCcontrol), Gene Tools
(morph18), Midland Certiﬁed Reagents Company (AG30,
SCR30, MIX30, Fluc13) and Keck Oligonucleotide Synthesis
Facility (Yale University) (AG19, DNA18). Duplex target
oligonucleotides (G3Y, G3R) were synthesized by Oligos
Etc. When the chemical modiﬁcation did not provide protec-
tion against exonuclease degradation, which is necessary for
cell targeting experiments, 30 ends were synthesized to contain
a3 0 propylamine group, using the C3 amino-CPG from Glen
Research. The following oligonucleotides contain a 30 propyl-
amine group: G3TmC18, G3pUmC18, AG30, SCR30 and
MIX30. Three terminal phosphorothioate linkages were syn-
thesized on the 30 end of 20-O-Me18 and Fluc13 has terminal
phosphothioate linkages on both ends. Pyrimidine TFO
sequences and modiﬁcations are listed in Figure 1. The
sequences for the control oligonucleotides are as follows:
AG30, 50-AGGAAGGGGGGGGTGGTGGGGGAGGGG-
GAG-30; SCR30, 50-0GGAGGAGTGGAGGGGAGTGAGG-
GGGGGGGG-30; MIX30, 50-AGTCAGTCAGTCAGTCAG-
TCAGTCAGTCAG-30; Fluc13, 50-TGGTAAAGCCACCA-
TGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCG-
CC-30; UmCcontrol, 50-cucucucucuuuuuuu-30 (c = 5meC, u =
pdU); LNAcontrol, 50-TtTTCtTTTtTCTtTTCt-30 (t = LNA);
AG19, 50-AGGAAGGGGGGGGTGGTGGG-30; DNA18,
50-TTTTCTTTTTTCTTTTCT-30.
The pSupFTC18 shuttle vector, derived from pSP189 (23),
carries two copies of the supF gene, each with a distinct
mutation, ﬂanking an 18-bp A-rich homopurine/homopyr-
imidine target site [the TC18 site from pLSG3 (13)]. These
mutations were created using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene). These mutations result in
inactive tRNAs which lack the ability to suppress the
amber mutation in the lacZ gene in MBM7070 Escherichia
coli which are used as indicator hosts for this recombination
assay (24).
The plucTC18 vector was derived from a plasmid construc-
ted by subcloning the ﬁreﬂy luciferase gene Fluc+ (pGL3-
Basic Vector; Promega) into pcDNA5/FRT (Invitrogen)
(25). The TC18 target site was inserted 40 bp upstream of
the Fluc+ start site. Site-speciﬁc mutagenesis was used to
create a stop codon at bp 13 downstream from the start codon.
The pRLTC18 vector was constructed by adding the TFO
target site [the TC18 site from pLSG3 (13)] into the multiple
cloning region of the pRL-CMV vector (Promega).
Third-strand binding assays
Third-strand binding was measured using gel mobility shift
assays under native conditions. Two complementary 30mers
(G3Y, G3R) containing the TC18 target from pLSG3 (repres-
enting bp 76–105) were synthesized. Duplex DNA was
prepared by mixing 1000 pmol of each 30mer together with
50 mM NaCl and incubating at 85 C for 20 min and cooling to
room temperature before end-labeling with T4 polynucleotide
kinase (New England BioLabs) and [g-
32P]ATP (Amersham
Biosciences). Duplex was gel puriﬁed, electroeluted and
ﬁltered by Centricon (Millipore). A ﬁxed concentration of
duplex at 5 · 10
 8 M was added to binding reactions with
increasing concentrations of oligonucleotides in 20 mlo f
10 mM Tris (pH 7.2) and selected concentrations of MgCl2
(0.1 or 10 mM) and KCl (0 or 140 mM). Binding for full
DEED18 was carried out at pH 7.6 with the addition of
1 mM spermine. Binding assays were also carried out at
pH 5.4, in which case 40 mM Tris–acetic acid was substituted
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16 h unless otherwise speciﬁed.
Samples bound at pH 7.2 were loaded onto 15% poly-
acrylamide gels [acrylamide/bisacrylamide (19:1)] containing
17.8 mM Tris and 17.8 mM boric acid (pH 7.2) and 10 mM
MgCl2 and the gels were run in the same concentration of
Tris-boric acid and MgCl2 at 60 V for 6 h at 23 C. For sam-
ples bound at pH 5.4, 15% polyacrylamide gels containing
40 mM Tris–acetate and 10 mM MgCl2 were used and gels
were run in buffers of the same concentration of Tris–acetate
and MgCl2 at 60 V for 6 h at 23 C.
Shuttle vector recombination assay
Monkey COS-7 cells were obtained from ATCC (1651-CRL)
and grown in DMEM/10% fetal bovine serum (FBS) (Gibco).
Cells were grown to 50–70% conﬂuency and cell transfection
was performed with GenePORTER2 (Gene Therapy Systems,
Inc.). Cells were transfected with 1 mg of pSupFTC18 fol-
lowed 24 h later by a second, separate transfection with
1 mg of oligonucleotide. Cells were harvested at 48 h after
oligonucleotide transfection and shuttle vector DNA was iso-
lated by a modiﬁed alkaline lysis procedure, as described pre-
viously (6). Vector samples were used to transform indicator
bacteria [MBM7070 [lacZ(Am)] (23)] by electroporation
(Bio-Rad; settings 25 mF, 250 W and 1800 V; 0.1 cm electrode
gap cuvette), and colonies were screened for supF function
by growth on plates supplemented with 75 mg/ml ampicillin,
210 mg/ml X-Gal and 200 mg/ml isopropyl-b-D-
thiogalactopyranoside. Recombination events were indicated
by wild-type blue colonies in a background of white colonies.
Chinese hamster ovary (CHO) cell transfection and
luciferase assay
CHO cells were obtained from Invitrogen and grown in F12/
10% FBS (Gibco) supplemented with 2 mM L-glutamine
(Gibco) and 100 mg/ml Zeocin (Invitrogen). CHO cells
were transfected and the luciferase activity was assayed as
described previously (25). Brieﬂy, 24 h prior to transfection,
12-well plates were seeded with 5 · 10
4 cells/well. plucTC18
was preincubated overnight with Fluc13 (an oligonucleotide
containing the wild-type luciferase sequence for the mutated
Figure 1. Oligonucleotide sequences and chemical structures. (A) Duplex
target and oligonucleotide modifications. The third-strand binding site is in-
dicatedin uppercase lettersin the duplex(G3Y/G3R)usedfor bindingstudies.
For the oligonucleotides, lower case letters indicate modified nucleotides with
the specific chemistry as indicated in the name of the oligonucleotide. Upper
case letters indicate unmodified nucleotides. All internucleoside linkages in
amidate18 are N30!P50 phosphoramidate (amidate)-modified. DEED-modi-
fied nucleotides are present in partial DEED (pDEED18) and full DEED18 as
indicated. G3TmC18 contains 5-methyl-20-deoxycytidines (5meC) in place
of cytidines. G3pUmC18 contains 5meC-modifications on all cytidines and
all thymines are replaced by pdU. LNA18 contains unmodified nucleotides
alternating with 20-O, 40-C-methylene bridged or LNA-modified nucleotides.
20-O-Me18 contains 20-O-Me-modified nucleotides and all cytidines have
5meC-modifications.20-AE18contains20-AE-modifiednucleotidesatthefour
lower case letter positions, while the upper case positions have 20-O-Me
modifications and all positions also have either 5meC-modifications or 5-
methyl-20-deoxyuridine modifications. All nucleotides in morph18 are mor-
pholino (morph)-modified. (B) Structures of the chemical modifications.
N30!P50 phosphoramidate (amidate); N,N-diethylethylenediamine (DEED);
5-methyl-20-deoxycytidine (5meC); 5-(1-propynyl)-20-deoxyuridine (pdU);
20-O,40-C-methylene bridged or locked nucleic acid (LNA); 20-O-methyl-
ribose (20-O-Me); 20-O-(2-aminoethyl)-ribose (20-AE); morpholino (morph).
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10 mM Tris (pH 7.2) at 37 C. Cells were transfected with
GenePORTER2 as described above. Each transfection deliv-
ered 0.3 mg of plasmid, donor and TFO per well. Cells were
collected 48 h post-transfection by rinsing twice with PBS
followed by lysis with 1· Passive Lysis Buffer (Promega).
Luciferase activity was measured using the Promega Dual
Luciferase Kit and only the LAR II substrate. The total protein
in the cell lysate was determined via Bradford protein
assay (26).
In vitro repair synthesis assay
Repair reactions were carried out as described previously (27),
with several modiﬁcations. HeLaScribe Nuclear Extract
in vitro Transcription Grade (Promega) was used. The
pRLTC18 plasmid (500 ng) containing the TC18 target
sequence was preincubated with 1 mM TFO (37 C, 18 h,
10 mM Tris, pH 7.2 and 10 mM MgCl2). As a positive con-
trol, one sample was incubated with sterile water in place of
oligonucleotide, this sample was then damaged by UVC
radiation treatment (2 inches, 30 s). The DNA was added to
HeLa cell-free extracts with [a-
32P]dCTP and supplemented
as described previously (27). Samples were incubated for
3 h at 30 C and the reactions were stopped as previously
described (27). Substrate plasmid DNAs were isolated from
the reaction by phenol/chloroform/iso-amyl alcohol extraction
and EtOH precipitation. The isolated vector DNAs were
linearized by XhoI digestion and the samples were analyzed
by gel electrophoresis. DNA repair synthesis was quantiﬁed
by measuring [a-
32P]dCTP incorporation using a phosphor-
imager (Storm 860; Molecular Dynamics, Amersham Pharma-
cia Biotech). The quantiﬁed value of the UVC-treated sample
was set to 100% and used to normalize the measurements
of the other samples.
Shuttle vector assay in repair-deficient and
corrected cells
XP12BE cells (deﬁcient in the NER factor, XPA) were
obtained from Coriell Cell Repositories (GM04429) and
grown in MEM/10% FBS (Gibco). The shuttle vector recomb-
ination assay was performed as described above except that,
in some cases, the cells were also transfected with 1 mgo fa
plasmid containing XPA cDNA [XPA cDNA with a His tag on
the C-terminus cloned into the multiple cloning site of
pcDNA3.1 (Invitrogen)] at the same time the cells were trans-
fected with the pSupFTC18. XPA expression was veriﬁed by
western blot. Brieﬂy, cells were lysed (at 48 and 72 h post-
transfection) with RIPA buffer (150 mM NaCl and 0.1% SDS)
and 100 mg of total protein per sample was resolved on 12%
SDS–PAGE gels. Proteins were detected by standard immun-
oblot procedures using XPA (28) and tubulin (clone B-5-1-2;
Sigma) primary antibodies.
Serum stability assay
Each oligonucleotide was 50 end-labeled at a concentration of
1 mM with [g-
32P]ATP (Amersham) using T4 polynucleotide
kinase (New England BioLabs) for 1 h, followed by heat
inactivation for 20 min at 70 C. An aliquot of 5 ml of end-
labeled oligonucleotide was added to 100 ml of FBS (Gibco)
and incubated at 37 C. Aliquots were removed at 0–24 h and
added to an equal volume of formamide dye, before being run
on a 20% denaturing polyacrylamide gel. Visualization and
quantiﬁcation of intact oligonucleotide was performed using
a phosphorimager.
RESULTS
TFO target site and oligonucleotide modifications
To examine the ability of triplexes formed in the pyrimidine,
parallel motif to induce recombination and repair, we evalu-
ated a series of chemically modiﬁed pyrimidine TFOs each
designed to bind to an 18 bp A-rich duplex target site
(Figure 1). The modiﬁcations included amidate and DEED
internucleoside linkages and 5meC and pdU base substitu-
tions. Sugar modiﬁcations included LNA, 20-O-Me and
20-AE substitutions. Morpholino TFOs consist of both sugar
and backbone changes (Figure 1).
We chose these modiﬁcations because either they have been
shown to enhance intracellular delivery of psoralen conjugates
to target genes [amidate (29–33), DEED (18), 5meC (13,34),
pdU (13,34,35), 20-O-Me (14) and 20-AE (14)] or they have
been found to provide enhanced third-strand binding in vitro
[LNA (36–38) and morpholino (39,40)]. In the case of the
DEED modiﬁcation, enhanced chromosome targeting has
been demonstrated only in the purine motif. However, the
ability of the DEED internucleoside substitution to confer a
potentially advantageous positive charge on the TFO promp-
ted us to consider pyrimidine TFOs with either full or partial
DEED modiﬁcations.
Unless otherwise speciﬁed, all TFOs contained phosphodi-
ester backbones. In some cases, all nucleotides were modiﬁed
in a given TFO while in other cases only selected ones
were modiﬁed, as indicated (Figure 1). The C residues in
G3TmC18, G3pUmC18, 20-O-Me18 and 20-AE18 were sub-
stituted with 5meC, because this modiﬁcation has been shown
to enhance third-strand binding at physiological pH (41,42).
Nucleotides in 20-AE18 not containing the 20-AE modiﬁcation
were synthesized to contain 20-O-Me modiﬁcations.
In vitro binding measurements
The binding afﬁnities of TFOs with the modiﬁcations
described above were compared under a series of conditions
as determined by gel mobility shift assays in non-denaturing
gels. Binding was quantiﬁed and equilibrium dissociation
constants (Kd, representing TFO concentrations yielding
half-maximal binding) were determined. Because stable trip-
lex formation is dependent on Mg
2+ and sensitive to K
+
(43,44), we tested binding in either 0.1 or 10 mM MgCl2
and either 0 or 140 mM KCl (both conditions at pH 7.2).
In recognition of the possible pH dependence of binding by
certain TFOs, we also tested binding at pH 5.4 (in 10 mM
MgCl2 and without KCl).
Under conditions where the minimally modiﬁed TFO,
G3TmC18, formed triplexes (pH 5.4, 10 mM MgCl2 and
0 mM KCl), all of the chemically modiﬁed TFOs formed
triplexes (Figure 2). However, there was a range of binding
afﬁnities (Figure 2 and Table 1). The best binding was seen
with the amidate, LNA, 20-AE, pdU and 20-O-Me-modiﬁed
oligonucleotides, with Kd values of 2.8 · 10
 10, 3.0 · 10
 10,
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 10, 4.5 · 10
 10 and 4.6 · 10
 10 M, respectively
(Figure 2 and Table 1). G3TmC18, morph18 and partially
modiﬁed DEED oligonucleotides showed lower binding
afﬁnities, and the full DEED18 showed the lowest binding
(Figure 2 and Table 1).
At neutral pH with 10 mM MgCl2, the 20-O-Me, LNA,
20-AE and amidate-modiﬁed TFOs showed strong binding
with Kd values of 1.5 · 10
 10, 2.7 · 10
 10, 6.0 · 10
 10
and 8.0 · 10
 10 M, respectively (Figure 2 and Table 1).
The pdU and 5meC-modiﬁed TFOs showed  10-fold weaker
binding and the morpholino-modiﬁed TFO showed 1000-fold
weaker binding. Neither of the DEED-modiﬁed oligonuc-
leotides (partial or full) showed any binding at neutral pH.
Under physiological conditions (pH 7.2, 0.1 mM MgCl2 and
140 mM KCl), the amidate, 20-AE, LNA and pdU-modiﬁed
TFOs showed the strongest binding with Kd values of
1.0 · 10
 8, 2.0 · 10
 8, 2.5 · 10
 8 and 9.0 · 10
 8 M,
respectively. G3TmC18 showed slightly weaker binding,
and the morpholino and the 20-O-Me-modiﬁed TFO showed
even weaker binding. The DEED-modiﬁed TFOs showed no
detectable binding under these conditions.
TFO-induced recombination in COS-7 cells
To test triplex-induced recombination by pyrimidine TFOs,
we constructed an SV40-based shuttle vector similar to pSup-
FAR usedinpreviouswork totestpurineTFOs (20). However,
in this case, we designed the vector to contain the 18 bp A-rich
target site used in the binding assays above. This site is inser-
ted between two copies of the supF gene, each with an inac-
tivating point mutation, at bp 163 in the upstream gene and at
bp 115 in the downstream gene (Figure 3A). The 50 mutation is
33 bp from the beginning of the TFO binding site, while the 30
mutation is 24 bp away from the end of the site. Recombina-
tion between the two genes can generate a functional supF
gene, which can be scored upon shuttle vector transformation
into indicator bacteria following vector DNA rescue from the
COS-7 cells.
The plasmid vector was pre-transfected into the COS-7 cells
toestablishtheepisomaltargetinthesecells.Onedaylater,the
cells were transfected with the TFOs and maintained in culture
for 48 h to allow for triplex formation and possible induced
recombination. As a negative control to establish the back-
ground frequency of recombination in this assay, we included
in each experiment cells transfected with vector but mock-
transfected the next day without TFO. The vector DNAs were
harvested from the cells and analyzed for recombination
Figure 2. Third-strand binding under selected conditions as determined by gel mobility shift analysis. The first lane in each panel contains duplex alone
(0 concentration of TFO), the second lane contains 10
 5 M oligonucleotide, and each subsequent column contains a 10-fold dilution. Third-strand binding
conditions: (A) pH 5.4, 10 mM MgCl2 and 0 mM KCl; (B) pH 7.2, 10 mM MgCl2 and 0 mM KCl; (C) pH 7.2, 0.1 mM MgCl2 and 140 mM KCl. The bands
of reduced mobility relative to the duplex alone represent triplex formation.
Table 1. Binding of chemically modified pyrimidine oligonucleotides to an
18 bp A-rich site
a
Oligonucleotide pH 5.4
(10 mM MgCl2
and 0 mM KCl)
pH 7.2
(10 mM MgCl2
and 0 mM KCl)
pH 7.2
(0.1 mM MgCl2
and 140 mM KCl)
amidate18 2.8 · 10
 10 8.0 · 10
 10 1.0 · 10
 8
pDEED18 3.0 · 10
 8 None None
full DEED18 1.0 · 10
 6 None
b None
G3TmC18 3.0 · 10
 9 7.0 · 10
 9 3.0 · 10
 7
G3pUmC18 4.5 · 10
 10 7.0 · 10
 9 9.0 · 10
 8
20-O-Me18 4.6 · 10
 10 1.5 · 10
 10 8.0 · 10
 6
20-AE18 4.0 · 10
 10 6.0 · 10
 10 2.0 · 10
 8
LNA18 3.0 · 10
 10 2.7 · 10
 10 2.5 · 10
 8
morph18
c 3.0 · 10
 8 3.5 · 10
 6 5.1 · 10
 6
aBinding affinities were calculated as equilibrium dissociation constants (Kd)
under the indicated conditions as determined by gel mobility shift assay under
non-denaturing conditions. Kd values are given in molarity. Binding was done
for 16 h at 37 C unless otherwise specified.
bBinding was carried out at pH 7.6 with 1 mM spermine.
cBinding was performed at 23 C.
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experiments by comparison to the plasmid only (no oligo-
nucleotide) background and presented as recombination
frequency. Transfection of cells with the amidate18 and
G3pUmC18 TFOs gave the highest levels of induced recomb-
ination, at 0.37 and 0.31%, respectively; whereas G3TmC18,
20-AE18 and morph18 gave lower frequencies of 0.14, 0.14
and 0.13%, respectively. The 20-O-Me, LNA and DEED TFOs
had minimal effects over background. The control TFOs,
UmCcontrol, LNAcontrol, AG30, SCR30 and MIX30 showed
little effect over background.
To further control for sequence speciﬁcity, we tested
induced recombination by the amidate18 and G3pUmC18
TFOs using a different shuttle vector, pSupFAR, as a target
in the cells. pSupFAR contains two mutant supF genes ﬂank-
ing a 30 bp G-rich polypurine target site suitable for triplex
formation in the purine motif (3). In previous work, we have
shown that a G-rich TFO, AG30, can bind with high afﬁnity to
Figure 3. Induced recombination mediated by pyrimidine TFOs. (A) Schematic representation of the pSupFTC18 vector. This SV40-based vector contains two
mutantsupFgenesintandem.TheupstreammutantsupFgene,supF163,containsaC-to-Tpointmutationatnucleotideposition163.ThedownstreammutantsupF
gene, supF115, contains a G-to-A point mutation at nucleotide position 115. In between the two mutant supF genes is an 18 bp A–T-rich homopurine/homo-
pyrimidine target site. The chemically modified oligonucleotides described in Figure 1A were designed to bind to this target sequence. (B) Triplex-induced
recombination in COS-7 cells. The plasmid described in (A) was pre-transfected into COS-7 cells followed 1 day later by transfection of the indicated oligonucleo-
tidesormocktransfection.After48h,shuttlevectorDNAwasisolatedandtransformedintoindicatorbacteriatoanalyzesupFgenefunctionandallowquantification
of recombination events. Percent recombination was calculated by the ratio of the number of blue colonies to total colonies.
Nucleic Acids Research, 2005, Vol. 33, No. 11 3497the third-strand binding site in pSupFAR (3). AG30 shows
no detectable binding to the A-rich polypurine site found
in pSupFTC18; conversely, TC-rich pyrimidine TFOs show
no binding to the G-rich site in pSupFAR (data not shown).
We found that while transfection of amidate18 and
G3pUmC18 into COS-7 cells can induce recombination in
pSupFTC18, neither has an effect on recombination in pSup-
FAR in the same cell assay (nor do any of the other modiﬁed
pyrimidine TFOs tested) (Figure 4). In contrast, AG30 can
induce recombination in pSupFAR in COS-7 cells but has
no effect on recombination in pSupFTC18 (Figure 4).
Hence, the effects of the amidate18, G3pUmC18 and AG30
TFOs are sequence-speciﬁc, based on both oligonucleotide
and target site controls.
TFO-induced recombination in CHO cells
To test pyrimidine-induced recombination in a different
episomal target, we constructed the plucTC18 plasmid,
which is a vector containing a pyrimidine TFO target adjacent
to a mutated luciferase reporter gene, similar to a vector
used in previous work studying targeting in the purine
motif (25). The TFO binding site is 40 bp upstream from
the start site of the luciferase gene, and a nonsense mutation
that inactivates the luciferase gene is 13 bp downstream from
the start site. In this assay, recombination induced by TFO
binding occurs between the plasmid and a separate donor
oligonucleotide (a 50mer) containing the wild-type luciferase
sequence in the region of the mutation. The amidate18 was
found to induce recombination at a frequency of 0.11%
(Figure 5B), whereas the 20-O-Me- and 20-AE-modiﬁed
TFOs showed minimal levels of induced recombination
above background.
Pyrimidine TFO-induced repair in HeLa cell extracts
Because previous work had shown a correlation between the
ability of purine TFOs to induce recombination and the ability
of the triplexes they form to induce repair, we assayed for
induced repair synthesis in HeLa cell-free extracts on plasmid
substrates containing pyrimidine motif triplexes. The substrate
for DNA repair was a plasmid incubated in the presence or
absence of TFO. The amount of DNA repair-associated
synthesis was measured based on the level of incorporation
of [a-
32P]dCTP into the plasmid. This is a well-established
assay for measuring repair provoked by a variety of DNA
lesions (45–47). Amidate18 and G3pUmC18 showed the high-
est level of induced repair activity at 42 and 66%, respectively,
as compared with UVC damage set at 100% activity
(Figure 6A and B). G3TmC18 and LNA18 produced lower
repair activity (Figure 6A and B).
Role of NER in induced recombination by
pyrimidine TFOs
To determine if the induced recombination in cells by the
amidate18 TFO is due to the NER pathway, a shuttle vector
Figure4.Sequence-specificityoftheTFO-inducedrecombination.(A)Triplex-inducedrecombinationwithapyrimidinemotiftarget.Cellspre-transfectedwiththe
dual supF plasmid containing the 18 bp A–T-rich site, pSupFTC18, were transfected the next day with lipid reagent alone or with the indicated TFOs. AG30 and
SCR30areG-richTFOsandMIX30hasamixedsequence.ShuttlevectorrescueandanalysiswereperformedasforFigure3.(B)Triplex-inducedrecombinationwith
apurinemotiftarget.Cellspre-transfectedwithadualsupFplasmidcontaininga30bpG-richsite,pSupFAR,weretransfected1daylaterwithlipidreagentaloneor
withtheindicatedTFOs.Analysisofrecombinationeventswasperformedasabove.Amidate18andG3pUmC18bindwithhighaffinitytotheA-richtargetsiteinthe
intergenic region in pSupFTC18 but not to the G-rich site in pSupFAR. AG30 binds well to the site in pSupFAR but not to that in pSupFTC18.
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formed in XP12BE cells. These cells are SV40 transformed
ﬁbroblasts isolated from a patient lacking the Xeroderma Pig-
mentosum complementation group A protein (XPA, a recog-
nition protein in the NER pathway). The amidate18 TFO was
unable to induce recombination in XP12BE cells (Figure 6C).
However, with the expression of XPA cDNA, induced
recombination by amidate18 was detected (Figure 6C). The
expression of XPA in the cDNA-transfected cells was con-
ﬁrmed by western blot (Figure 6D).
Nuclease resistance of pyrimidine TFOs
To test the possibility that differences in resistance to nucle-
ases of the various TFOs could be responsible for the observed
differences in induced recombination frequencies, we tested
the stability of selected TFOs in serum. The 50 end-labeled
TFOs were added to FBS and aliquots were removed at time
points from 0 to 24 h to measure the quantity of full-length
oligonucleotide by gel electrophoresis and autoradiography.
After 1 h in serum, most of the chemically modiﬁed pyrimi-
dine TFOs were intact, except for the unmodiﬁed-TFO
DNA18 and the 5meC-modiﬁed TFO G3TmC18 (Figure 7).
After 3 h, the amidate18, LNA18, 20-O-Me18, 20-AE18 and
the G-rich TFOs all showed that >50% remained intact. The
G3pUmC18 TFO showed that  36% oligonucleotide was
intact at 3 h. By 6 h, only the 20-AE18 and the amidate18
pyrimidine motif TFOs showed >50% intact; the G3pUmC18
TFO showed  25% intact. In all cases, <10% of the pyrimi-
dine TFOs tested remained intact at 12 h. Interestingly, two G-
rich TFOs, AG30 and AG19, showed higher levels of nuclease
resistance, with >50% oligonucleotide remaining intact at
24 h (Figure 7) and persisting at this level even up to 72 h
(data not shown). This serum stability shown by the G-rich
TFOs may, in part, account for their documented effectiveness
for gene targeting in vivo following systemic administration
in mice (5).
Figure 5. Intermolecular induced recombination mediated by pyrimidine
TFOs. (A) Schematic representation of the plucTC18 construct. The plasmid
contains the pyrimidine triplex binding site located 40 bp upstream of the start
codon for the firefly luciferase gene. The luciferase gene has a nonsense
mutationat 13 bp downstreamfrom the start codon.(B) Percentrecombination
in CHO cells. Plasmid, TFO, and the donor oligonucleotide (Fluc13) were
co-transfected into CHO cells. After 48 h, cells were lysed and recombination
was measured based on relative light units and normalized to protein.
Figure 6. Pyrimidine motif TFOs and DNA repair. (A) Pyrimidine triplex-
induced DNA repair in HeLa cell extracts. TFOs and plasmids were co-
incubated in HeLa cell-free extracts supplemented with [a-
32P]dCTP. Induced
DNA repair synthesis was measured by visualization and quantification of
incorporation of [a-
32P]dCTP into the plasmid. As a positive control, plasmid
alonewastreatedwithUVCirradiation.(B)Quantificationofinducedrepairas
measured by [a-
32P]dCTP incorporation in (A); normalized to UVC-treated
plasmid representing 100% repair activity. (C) Dependence of triplex-induced
recombination on XPA. XP12BE (XPA-deficient) cells were transfected with
thedualsupFreporterconstructcontainingthepyrimidinemotiftriplexbinding
site and then transfected or not with the amidate18 TFO. Parallel samples were
also transfected with XPA cDNA at the same time as the dual supF vector.
Induced recombination was assayed as in Figures 3 and 4. (D) Levels of XPA
expression in XP12BE cells versus XP12BE cells transfected with an XPA
cDNAconstruct.XP12BEcellsandXP12BEcellstransfectedwithXPAcDNA
were collected at 48 and 72 h post-transfection and expression of XPA was
detected by western blot.
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In the work reported here, we tested a series of TFOs with
selected chemical modiﬁcations for their ability to bind as
third strands in the pyrimidine motif under a variety of
in vitro conditions, for their ability to induce recombination
in two different cell-based episomal targeting assays, and for
their ability to induce repair in cell extracts. We found that
high-afﬁnity in vitro binding was necessary but not sufﬁcient
for increased intracellular activity. Certain modiﬁcations that
provide for enhanced in vitro binding were only minimally
effectiveatincreasingtheabilityofTFOstoinducerecombina-
tion in cells or to stimulate repair in cell extracts, while others
(amidate18 and G3pUmC18) stood out in the initial screen and
their activity held up under close evaluation (showing both
high third-strand binding afﬁnity and effective intracellular
activity). These differences cannot simply be attributed to
differential nuclease resistance.
The modiﬁed TFOs with the highest binding afﬁnities
under physiological conditions in vitro (low Mg
2+, high K
+
and neutral pH) were amidate18, G3pUmC18, 20-AE18
and LNA18. Of these, only the amidate and pdU-modiﬁed
TFOs mediated increases in recombination frequencies over
background, 3.4- and 2.8-fold, respectively. The recombina-
tion frequencies in the COS-7 episomal shuttle vector assay
produced by amidate18 (0.37%) and G3pUmC18 (0.31%)
are comparable with the recombination frequency induced
by AG30 in a similar shuttle vector assay (0.40%). These
recombination frequencies are based on targeting an episomal,
not a chromosomal, target. Transfection of the episomal target
24 h before the oligonucleotide transfection allowed for chro-
matin assembly on the target plasmid (48). In the purine motif,
similar mutagenesis and recombination frequencies have been
established in episomal and chromosomal targets using G-rich
TFOs with both targets (4,6,17,49).
Using a second episomal targeting assay based on inter-
molecular recombination in a luciferase reporter gene, similar
results were seen with the amidate18 TFO, with a recombina-
tion frequency of 0.11% (which is a 48-fold induction of
recombination compared with recombination by donor DNA
alone in this assay). Thus, in two distinct episomal targeting
systems in cells, the amidate18 TFO was seen to induce
recombination in the absence of covalent adduct formation.
Additionally, the amidate18 and the G3pUmC18 TFOs
induced repair in cell extracts. In cells, the induction of recom-
bination in the shuttle vector assay by amidate18 was found to
be dependent on XPA, consistent with the in vitro repair
results and further suggesting that triplexes formed by amid-
ate18 induce recombination in a repair-dependent manner.
Hence, while several of the chemically modiﬁed TFOs in
the pyrimidine motif were found to bind well as third strands
under physiological conditions in vitro, only the amidate18
and G3pUmC18 TFOs were seen to induce recombination and
repair. One explanation consistent with our results would be
that the triplexes formed by the 20-AE and LNA-modiﬁed
TFOs are less effective at provoking DNA repair and thereby
less effective at inducing recombination. Our prior work with
purine motif TFOs indicated that triplexes can be recognized
as ‘lesions’ in the DNA by factors in the NER pathway, lead-
ing to induced repair and recombination (4,20,27). Our current
results suggest that the same is true for the pyrimidine motif
triplexes formed by amidate18 or G3pUmC18 TFOs.
Conceptually, this recognition is likely to result from helical
alterations caused by triplex formation (50). Interestingly,
Asensio et al. (22) found in an NMR-based structural analysis
of pyrimidine motif triplexes that the degree of duplex helical
distortion can be inﬂuenced by substitutions at the 20-position
of the ribose on the TFO. Comparing TFOs with 20-deoxy
(DNA), 20-OH (RNA) and 20-O-methyl (20-O-Me) ribose
moieties, they found that the relative degrees of distortion
were DNA > RNA > 20-O-Me. Hence, RNA-like substitution
at the 20-position in the TFO, which tends to promote a C3-
endo sugar conformation (51), appears to reduce the helical
distortion that occurs upon third-strand binding.
TheTFOs showingthe highestlevels of induced recombina-
tion were amidate18 and G3pUmC18 in the pyrimidine
motif and AG30 in the purine motif. All of these contain
DNA-like deoxyribose. In contrast, the 20-AE18 and
LNA18 TFOs have RNA-like 20-substituted sugars. In fact,
the LNA 20-substitution (consisting of the 20-O, 40-C-methyl-
ene bridge) locks the ribose into the RNA-like C3-endo con-
formation (52). This is proposed to be an advantage for triplex
formation because it may serve to pre-organize the TFO into a
uniform conformation favorable to third-strand binding (52),
but it may also serve to minimize the resulting helical distor-
tion. Therefore, based on this model, it is possible that the
amidate18, G3pUmC18 and AG30 TFOs may create triplexes
that are more distorting than those produced by the 20-AE18
and LNA18, resulting in an increased ability of the resulting
triplexes to provoke DNA repair (as shown) and thereby
stimulate recombination.
In conclusion, the work reported here demonstrates that
non-covalent pyrimidine TFOs, when appropriately modiﬁed,
can mediate high-afﬁnity binding, induction of recombination
in cells and induction of repair in cell extracts, at levels similar
to those seen with G-rich purine TFOs at their respective target
sites. These results expand the number of possible reagents for
targeted genome modiﬁcation.
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